BOTHELL, WA, and VANCOUVER, Aug. 10 /CNW/ - OncoGenex Pharmaceuticals,
Inc. (NASDAQ: OGXI), today announced that the United States Patent and
Trademark Office (PTO) has issued United States Patent Number 7,569,551
entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2
Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug
candidate, OGX-011, to treat certain cancers. The patent, licensed from The
University of British Columbia, includes coverage for the method for treating
cancers that express the protein clusterin using OGX-011, or any other
clusterin antisense oligonucleotide, in combination with any chemotherapeutic
agent or radiation therapy.
"The issuance of this patent expands our intellectual property estate for
treating clusterin-expressing cancers using antisense therapy and provides us
with a broad patent that applies well beyond prostate cancer," said Scott
Cormack, President and CEO of OncoGenex. "Importantly, given that our current
Phase 3 plans include combining OGX-011 with chemotherapy, this patent
directly relates to our current method of using OGX-011."
OncoGenex Pharmaceuticals, Inc. owns or has licenses to approximately 67
granted or issued U.S. and foreign patents, and approximately 140 pending U.S.
and foreign patent applications worldwide. Composition of matter patents
covering OGX-011, OGX-427, SN2310, CSP-9222 and TOCOSOL(TM) have issued in the
U.S. and certain other jurisdictions. Additional patent applications covering
all of these products, as well as other technologies, are pending in the U.S.
and certain other countries. TRPM-2 is an historical name for clusterin, and
survives in some of the earlier patent filings.
About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address unmet needs in the treatment
of cancer. OncoGenex has a deep oncology pipeline, with each product candidate
having a distinct mechanism of action and representing a unique opportunity
for cancer drug development. OGX-011, the lead candidate that has completed
five Phase 2 clinical trials in prostate, lung and breast cancers, is designed
to inhibit the production of a specific protein associated with treatment
resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed
the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in
OGX-011, OGX-427 and OGX-225 utilize second-generation antisense
technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively
target and inhibit production of specific proteins in tumor cells. OncoGenex
and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225
and with respect to OGX-011, in its initial development. In 2008, OncoGenex
and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights
to OGX-011 and sole responsibility for development and related costs and
partnering decisions, subject to financial obligations to Isis. OncoGenex is
also solely responsible for development and related costs and partnering
decisions regarding OGX-427 and OGX-225. Key intellectual property related to
OGX-011, OGX-427 and OGX-225 were discovered by The University of British
Columbia and the Vancouver Prostate Centre, and were exclusively licensed to
More information about OncoGenex is available at www.oncogenex.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995, including, but not limited to, statements regarding the scope of
the claims in our issued patents, the nature and extent of our intellectual
property, the benefits provided by such issued patents and intellectual
property and our plans with respect to our clinical development activities.
Such forward-looking statements are subject to risks and uncertainties,
including, among others: the risk factors set forth in the Company's filings
with the Securities and Exchange Commission, including the Company's Annual
Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation
to update the forward-looking statements contained herein or to reflect events
or circumstances occurring after the date hereof, other than as may be
required by applicable law.
For further information:
For further information: OncoGenex Contact: Scott Cormack, President &
CEO, (604) 736-3678, email@example.com; Media and Investor Contact: Jason
Spark, Porter Novelli Life Sciences, (619) 849-6005,